
Norbert Blank

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6902304/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology, 2008, 47, 1185-1192.	0.9	252
2	Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features. Arthritis Research and Therapy, 2011, 13, R172.	1.6	133
3	Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatric Rheumatology, 2015, 13, 50.	0.9	100
4	Rituximab in the Treatment of Jo1 Antibody–associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response. Journal of Rheumatology, 2016, 43, 1566-1574.	1.0	99
5	Extracellular Vesicle Subtypes Released From Activated or Apoptotic T-Lymphocytes Carry a Specific and Stimulus-Dependent Protein Cargo. Frontiers in Immunology, 2018, 9, 534.	2.2	88
6	International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology, 2017, 56, 2102-2108.	0.9	84
7	Cholera toxin binds to lipid rafts but has a limited specificity for ganglioside GM1. Immunology and Cell Biology, 2007, 85, 378-382.	1.0	83
8	Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, 730-737.	0.5	82
9	Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. Annals of the Rheumatic Diseases, 2020, 79, 370-378.	0.5	60
10	Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Annals of the Rheumatic Diseases, 2020, 79, 1090-1097.	0.5	56
11	Atorvastatin Inhibits T Cell Activation through 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase without Decreasing Cholesterol Synthesis. Journal of Immunology, 2007, 179, 3613-3621.	0.4	55
12	Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. Rheumatology, 2016, 55, 689-696.	0.9	55
13	Stress Doppler echocardiography for early detection of systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Research and Therapy, 2015, 17, 165.	1.6	50
14	Apoptotic cell-derived membrane microparticles and IFN-α induce an inflammatory immune response. Journal of Cell Science, 2015, 128, 2443-53.	1.2	42
15	Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients. Journal of Rheumatology, 2016, 43, 66-74.	1.0	42
16	A fast, simple and sensitive method for the detection and quantification of detergent-resistant membranes. Journal of Immunological Methods, 2002, 271, 25-35.	0.6	35
17	Extracellular vesicles mediate intercellular communication: Transfer of functionally active microRNAs by microvesicles into phagocytes. European Journal of Immunology, 2017, 47, 1535-1549.	1.6	35
18	Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). Arthritis Research and Therapy, 2019, 21, 217.	1.6	34

Norbert Blank

#	Article	IF	CITATIONS
19	IL1-blocking therapy in colchicine-resistant familial Mediterranean fever. European Journal of Rheumatology, 2018, 5, 230-234.	1.3	28
20	Sarcoidosis and the occurrence of malignant diseases. Rheumatology International, 2014, 34, 1433-1439.	1.5	26
21	Reduced Right Ventricular Output Reserve in Patients With Systemic Sclerosis and Mildly Elevated Pulmonary Artery Pressure. Arthritis and Rheumatology, 2019, 71, 805-816.	2.9	25
22	Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression. American Journal of Hematology, 2020, 95, 1158-1169.	2.0	25
23	Risk factors for AA amyloidosis in Germany. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 1-7.	1.4	24
24	Obesity is a significant susceptibility factor for idiopathic AA amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 37-45.	1.4	24
25	Scleroderma Renal Crisis: Risk Factors for an Increasingly Rare Organ Complication. Journal of Rheumatology, 2020, 47, 241-248.	1.0	24
26	Familial Mediterranean fever in Germany: clinical presentation and amyloidosis risk. Scandinavian Journal of Rheumatology, 2013, 42, 52-58.	0.6	23
27	Activated human B cells induce inflammatory fibroblasts with cartilage-destructive properties and become functionally suppressed in return. Annals of the Rheumatic Diseases, 2016, 75, 924-932.	0.5	23
28	Evidence for genetic overlap between adult onset Still's disease and hereditary periodic fever syndromes. Rheumatology International, 2018, 38, 111-120.	1.5	20
29	Inhibition of sphingolipid synthesis impairs cellular activation, cytokine production and proliferation in human lymphocytes. Biochemical Pharmacology, 2005, 71, 126-135.	2.0	18
30	Lowâ€dose cyclophosphamide effectively mobilizes peripheral blood stem cells in patients with autoimmune disease. European Journal of Haematology, 2016, 97, 78-82.	1.1	17
31	Peripheral blood natural killer cell percentages in granulomatosis with polyangiitis correlate with disease inactivity and stage. Arthritis Research and Therapy, 2015, 17, 337.	1.6	14
32	Older age onset of systemic sclerosis – accelerated disease progression in all disease subsets. Rheumatology, 2020, 59, 3380-3389.	0.9	14
33	Familial early onset sarcoidosis with bone cysts and erosions. Skeletal Radiology, 2007, 36, 891-893.	1.2	11
34	Right heart size and function significantly correlate in patients with pulmonary arterial hypertension – a cross-sectional study. Respiratory Research, 2018, 19, 216.	1.4	11
35	Idiopathic Pericarditis—an Autoinflammatory Disease?. Current Rheumatology Reports, 2019, 21, 18.	2.1	9
36	Active but not inactive granulomatosis with polyangiitis is associated with decreased and phenotypically and functionally altered CD56dim natural killer cells. Arthritis Research and Therapy, 2016, 18, 204.	1.6	8

Norbert Blank

#	Article	IF	CITATIONS
37	The role of DMARDs in systemic sclerosis therapy. Rheumatology, 2006, 45, iii42-iii44.	0.9	6
38	SMC3 protein levels impact on karyotype and outcome in acute myeloid leukemia. Leukemia, 2019, 33, 795-799.	3.3	6
39	Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series. Annals of the Rheumatic Diseases, 2022, 81, 744-746.	0.5	5
40	Large Variability of Frequency and Type of Physical Therapy in Patients in the German Network for Systemic Sclerosis. Arthritis Care and Research, 2020, 72, 1041-1048.	1.5	3
41	Multiple Bone Lesions of Systemic Multifocal Fibrosclerosis. American Journal of Roentgenology, 2005, 185, 668-670.	1.0	2
42	THU0561â€CANAKINUMAB FOR THE TREATMENT OF ADULT ONSET STILLâ€ [~] S DISEASE TO ACHIEVE REDUCTIO ARTHRITIC MANIFESTATION AT WEEK 12: AN INVESTIGATOR-INITIATED MULTI-CENTRE, PLACEBO-CONTROLLED STUDY (CONSIDER). , 2019, , .	N OF	1
43	POS0834â€LONG-TERM OUTCOME OF SSC ASSOCIATED ILD: IMPROVED SURVIVAL IN PPI TREATED PATIENTS. Annals of the Rheumatic Diseases, 2021, 80, 670.2-671.	0.5	1
44	Targeting of Janus Kinases Limits Pro-Inflammatory but Also Immunosuppressive Circuits in the Crosstalk between Synovial Fibroblasts and Lymphocytes. Biomedicines, 2021, 9, 1413.	1.4	1
45	Remitting fever of unknown origin in a 20â€yearâ€old man. Arthritis Care and Research, 2012, 64, 459-464.	1.5	0
46	SAT0191â€Disease Progression in SSC-Overlap Syndromes is Significantly Different from Limited and Diffuse Cutaneous SSC. Annals of the Rheumatic Diseases, 2013, 72, A645.3-A646.	0.5	0
47	FRI0244â€Assessing organ involvement and current symptoms as indicators for disease progression in 3047 patient cohort. Annals of the Rheumatic Diseases, 2013, 71, 396.3-397.	0.5	0
48	A6.9â€Directed Transport of microRNAs from Apoptotic Cells to Phagocytes by Membrane-Coated Vesicles (MCVs). Annals of the Rheumatic Diseases, 2013, 72, A45.1-A45.	0.5	0
49	SAT0553â€Anti-Interleukin-1 Therapies and Pregnancy Outcome: an International Cohort. Annals of the Rheumatic Diseases, 2015, 74, 860.2-860.	0.5	0
50	AB0164â€Disease Progression in 282 Patients with Undifferentiated SSc – Data from The German Network for Systemic Scleroderma. Annals of the Rheumatic Diseases, 2016, 75, 952.2-952.	0.5	0
51	AB0169â€Evaluation of frequency and type of physical therapy in more than 3400 patients with systemic sclerosis. , 2017, , .		0
52	AB0181â€Diffusing capacity and clinical characteristics of patients with systemic sclerosis – data from the german network for systemic sclerosis. , 2017, , .		0
53	Diagnostic work up of an adult female patient with systemic AA amyloidosis revealing the cause of infantile mental retardation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 68-69.	1.4	0
54	P4534Reduced right ventricular contractile reserve in patients with systemic sclerosis and borderline pulmonary arterial pressures. European Heart Journal, 2018, 39, .	1.0	0

#	Article	IF	CITATIONS
55	AB0215â€A LATE ONSET OF SYSTEMIC SCLEROSIS IS ASSOCIATED WITH A MORE RAPIDLY PROGRESSING CLINICAL PHENOTYPE IN LCSSC PATIENTS. , 2019, , .		Ο
56	THU0339â€PULMONARY INVOLVEMENT AND OUTCOME IN SYSTEMIC SCLEROSIS (SSC) – ILD-PH AS AN IMPORTANT SUBSET. , 2019, , .		0
57	P3676Hemodynamic phenotypes in systemic sclerosis patients screened for pulmonary hypertension (PH): impact of the new definition of PH. European Heart Journal, 2019, 40, .	1.0	0
58	Response to: â€~ Correspondence on â€~Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension'' by Iudici et al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-219597.	0.5	0
59	POS1380â€LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH TRAPS (TUMOR NECRO Annals of the Rheumatic Diseases, 2021, 80, 972-973.	OSIS) Tj ET 0.5	Qq1 1 0.7843 0
60	Cohesin Subunit SMC3 Levels Impact on Karyotype and Outcome in Acute Myeloid Leukemia. Blood, 2018, 132, 2786-2786.	0.6	0
61	Significance of pulmonary involvement in systemic sclerosis (SSc) – data form the German SSc-network. , 2019, 73, .		Ο
62	Early treatment of Borderline Pulmonary Arterial Hypertension associated with Systemic Sclerosis: a randomized, controlled, double-blind, parallel group, proof-of-concept study. Pneumologie, 2019, 73, .	0.1	0
63	AB0584â€DOES ANTI-ACID TREATMENT INFLUENCE DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS INTERSTITIAL LUNG DISEASE (SSC-ILD)? DATA FROM THE GERMAN SSC-NETWORK. Annals of the Rheumatic Diseases, 2020, 79, 1589-1589.	0.5	0
64	Does anti-acid treatment influence disease progression in SSc-ILD? Data form the German SSc-network. Pneumologie, 2020, 74, .	0.1	0
65	Hemodynamic phenotypes in patients with systemic sclerosis screened for pulmonary hypertension (PH) – the impact of the new defintion of PH. Pneumologie, 2020, 74, .	0.1	0
66	Long term outcomes of immunmodulatory drugs in SSc-ILD – data rom the German SSc network. Pneumologie, 2020, 74, .	0.1	0